Opus Genetics (IRD) Other Gross PP&E Adjustments (2011 - 2026)
Opus Genetics (IRD) reported Other Gross PP&E Adjustments of -$1.2 million for Q1 2026, up 69.31% year-over-year from -$737691.2 in Q1 2025, and down 197.38% quarter-over-quarter from -$420000.0 in Q4 2025.
Opus Genetics (IRD) Other Gross PP&E Adjustments (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has 16 years of Other Gross PP&E Adjustments data on file, last reported at -$1.2 million in Q1 2026.
- Other Gross PP&E Adjustments for Q1 2026 came in at -$1.2 million, up 69.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.8 million (up 43.08% YoY), and the FY2025 annual result was -$420000.0, up 79.36% from the prior year.
- Other Gross PP&E Adjustments retreated to -$1.2 million in Q1 2026 per IRD's latest filing, from -$420000.0 in the prior quarter.
- Over five years, Other Gross PP&E Adjustments peaked at -$79000.0 in Q2 2022 and troughed at -$4.1 million in Q1 2025.
- A 5-year average of -$1.2 million and a median of -$948000.0 in 2024 frame the typical range for Other Gross PP&E Adjustments.
- The sharpest annual moves came in 2024 and 2025: Other Gross PP&E Adjustments plunged 1108.62% in 2024, then jumped 79.36% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$1.1 million in 2022, then slumped by 60.6% to -$1.8 million in 2023, then retreated by 12.43% to -$2.0 million in 2024, then jumped by 79.36% to -$420000.0 in 2025, then slumped by 197.38% to -$1.2 million in 2026.
- Business Quant data shows IRD's Other Gross PP&E Adjustments at -$1.2 million in Q1 2026, -$420000.0 in Q4 2025, and -$856000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -60,691.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -83,048.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -285.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -892,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -1.69 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Opus Genetics | 350.17 Mn | 290.21 Mn | - | -1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.25 Mn |
| Mar 31, 2026 | -1.25 Mn |
| Dec 31, 2025 | -420,000.00 |
| Dec 31, 2025 | -420,000.00 |
| Sep 30, 2025 | -856,000.00 |
| Sep 30, 2025 | -856,000.00 |
| Jun 30, 2025 | -3.23 Mn |
| Jun 30, 2025 | -3.23 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Sep 30, 2024 | -948,000.00 |
| Sep 30, 2024 | -948,000.00 |
| Jun 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | -1.61 Mn |
| Mar 31, 2024 | -1.61 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |